期刊
VACCINE
卷 27, 期 36, 页码 4923-4929出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.06.042
关键词
Streptococcus pyogenes; SpyCEP; Vaccine
资金
- Wellcome Trust
- UK NIHR Biomedical Research Centre
- Lee Spark Foundation
- Hammersmith Hospital Trustees Research Committee
- Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: researchfish
- Medical Research Council [G0800777] Funding Source: researchfish
- BBSRC [BB/E52708X/1] Funding Source: UKRI
- MRC [G0800777] Funding Source: UKRI
Currently there is no licensed vaccine against the human pathogen Streptococcus pyogenes. The highly conserved IL-8 cleaving S. pyogenes cell envelope proteinase SpyCEP is surface expressed and is a potential vaccine candidate. A recombinant N-terminal part of SpyCEP (CEP) was expressed and purified. AntiCEP antibodies were found to neutralize the IL-8 cleaving activity of SpyCEP. CEP-immunized mice had reduced bacterial dissemination from focal S. pyogenes intramuscular infection and intranasal infection. We also identified a functional SpyCEP-homolog protease SeCEP, expressed by the equine pathogen Streptococcus equi, which was able to cleave both human and equine IL-8. CEP-immunized mice also demonstrated reduced bacterial dissemination from S. equi intramuscular infection. Therefore immunization against SpyCEP may provide protection against other streptococci species with homologous proteases. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据